Heterogeneity in quality of care and cancer patient survival based on insurance coverage are the highlight of a report by researchers at the Institute for Population Health Improvement at the University of California Davis.
In an attempt to understand the existence of disparities in cancer care among Californians diagnosed with, and being treated for, cancer, researchers at the Institute for Population Health Improvement at the University of California Davis evaluated the stage at diagnosis, quality of treatment, and survival among those diagnosed with breast, colon, rectal, lung, and prostate cancer between 2004 and 2012. The outcome of the study? Significant disparities in survival and quality of care, dictated by the kind of insurance plan the individuals were enrolled in.
Using the California Cancer Registry (CCR), California’s population-based cancer surveillance system, the study evaluated 742,734 cases of the above listed cancers. The authors could successfully gather health insurance information for 703,603 cases, and based on the source of insurance, 7 categories were created: Medicare, Medi-Cal, Medicare-Medi-Cal dual eligible, private insurance, Department of Veteran’s Affairs (VA), Department of Defense (DOD), and uninsured.
The study found significant disparities based on the source of health insurance and gaps in quality of care, with Medi-Cal, Medicare-Medi-Cal dual eligibility, and the uninsured facing the highest number and largest disparities. Medi-Cal patients with breast, colon, and rectal cancer were more likely to be diagnosed at an advanced stage and have poor 5-year survival compared with those with alternate sources of insurance. Further, Medicare-Medi-Cal dual eligible were least likely to receive the specified treatment for breast and colon cancer.
A lag between diagnosis and treatment initiation was most common for VA patients with breast, colon, rectal, lung, and prostate cancers; however, they did fare better than patients with other types of insurance. Also, they were more likely to receive the recommended treatment compared with those covered by other health insurance.
“What’s particularly poignant is that we’re seeing these big disparate outcomes among groups in cancers where we have strong playbooks. There’s a body count and we’d like to figure out a better way to insure that all Californians are getting the recommended screening for these deadly cancers and treatment according to guidelines. We have a lot of work to do,” said Christina Clarke, a research scientist at the Cancer Prevention Institute of California and a consulting associate professor at the Stanford University School of Medicine, in reaction to the findings of this study.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More